Estimating the long-term effects of HPV vaccination in Germany

Horn J, Damm O, Kretzschmar MEE, Delere Y, Wichmann O, Kaufmann AM, Garbe E, Krämer A, Greiner W, Mikolajczyk RT (2013)
Vaccine 31(19): 2372-2380.

Zeitschriftenaufsatz | Veröffentlicht| Englisch
 
Download
Es wurde kein Volltext hochgeladen. Nur Publikationsnachweis!
Autor/in
Horn, J.; Damm, OliverUniBi; Kretzschmar, M. E. E.; Delere, Y.; Wichmann, O.; Kaufmann, A. M.; Garbe, E.; Krämer, AlexanderUniBi ; Greiner, WolfgangUniBi; Mikolajczyk, R. T.
Abstract / Bemerkung
In Germany, vaccination against the most oncogenic HPV types 16/18 is recommended by the Standing Committee on Vaccination (STIKO) for 12-17 year old girls since March 2007. We developed a dynamic mathematical model for the natural history and transmission of HPV infections to estimate the impact of vaccination on incidence and mortality of cervical cancer and its pre-stages, and on anogenital warts. We focused on an extensive model calibration to epidemiologic data for all stages of the natural history model as well as on a detailed implementation of cervical cancer screening modalities in Germany. Our model predicts first a substantial reduction of cervical cancer incidence and mortality over the next 30 years, which is mainly attributable to an increase in screening participation in the 1990s and not to HPV vaccination, followed by a further reduction attributable to vaccination. Over the next 100 years, HPV vaccination will prevent approximately 37% of cervical cancer cases even if vaccination coverage is only 50% (as currently observed in Germany). Consideration of cross-protection results in a further reduction of approximately 7% of all cervical cancer cases for the bivalent and about 5% for the quadrivalent vaccine in our model. Vaccination of boys was only reasonable if moderate to high vaccination coverage in girls was not achieved. Strategies should be implemented in Germany to increase HPV vaccination coverage among girls thereby making better use of the demonstrated benefits of the vaccine. (C) 2013 Elsevier Ltd. All rights reserved.
Stichworte
Mathematical modelling; Vaccination effects; Cervical cancer; HPV
Erscheinungsjahr
2013
Zeitschriftentitel
Vaccine
Band
31
Ausgabe
19
Seite(n)
2372-2380
ISSN
0264-410X
Page URI
https://pub.uni-bielefeld.de/record/2607268

Zitieren

Horn J, Damm O, Kretzschmar MEE, et al. Estimating the long-term effects of HPV vaccination in Germany. Vaccine. 2013;31(19):2372-2380.
Horn, J., Damm, O., Kretzschmar, M. E. E., Delere, Y., Wichmann, O., Kaufmann, A. M., Garbe, E., et al. (2013). Estimating the long-term effects of HPV vaccination in Germany. Vaccine, 31(19), 2372-2380. doi:10.1016/j.vaccine.2013.03.006
Horn, J., Damm, O., Kretzschmar, M. E. E., Delere, Y., Wichmann, O., Kaufmann, A. M., Garbe, E., Krämer, A., Greiner, W., and Mikolajczyk, R. T. (2013). Estimating the long-term effects of HPV vaccination in Germany. Vaccine 31, 2372-2380.
Horn, J., et al., 2013. Estimating the long-term effects of HPV vaccination in Germany. Vaccine, 31(19), p 2372-2380.
J. Horn, et al., “Estimating the long-term effects of HPV vaccination in Germany”, Vaccine, vol. 31, 2013, pp. 2372-2380.
Horn, J., Damm, O., Kretzschmar, M.E.E., Delere, Y., Wichmann, O., Kaufmann, A.M., Garbe, E., Krämer, A., Greiner, W., Mikolajczyk, R.T.: Estimating the long-term effects of HPV vaccination in Germany. Vaccine. 31, 2372-2380 (2013).
Horn, J., Damm, Oliver, Kretzschmar, M. E. E., Delere, Y., Wichmann, O., Kaufmann, A. M., Garbe, E., Krämer, Alexander, Greiner, Wolfgang, and Mikolajczyk, R. T. “Estimating the long-term effects of HPV vaccination in Germany”. Vaccine 31.19 (2013): 2372-2380.

14 Zitationen in Europe PMC

Daten bereitgestellt von Europe PubMed Central.

Reply to When flawed modeling justifies cost-effectiveness: Making sense of "Band-Aid" modeling.
Prinja S, Jyani G, Bahuguna P, Faujdar DS, Kumar R., Cancer 124(15), 2018
PMID: 29750834
Cervical Cancer Screening Programs in Europe: The Transition Towards HPV Vaccination and Population-Based HPV Testing.
Chrysostomou AC, Stylianou DC, Constantinidou A, Kostrikis LG., Viruses 10(12), 2018
PMID: 30572620
Clinical relevance and implications of HPV-induced neoplasia in different anatomical locations.
Prigge ES, von Knebel Doeberitz M, Reuschenbach M., Mutat Res Rev Mutat Res 772(), 2017
PMID: 28528690
An estimate of the public health impact and cost-effectiveness of universal vaccination with a 9-valent HPV vaccine in Germany.
Largeron N, Petry KU, Jacob J, Bianic F, Anger D, Uhart M., Expert Rev Pharmacoecon Outcomes Res 17(1), 2017
PMID: 27366939
Gene promoter methylation and protein expression of BRMS1 in uterine cervix in relation to high-risk human papilloma virus infection and cancer.
Panagopoulou M, Lambropoulou M, Balgkouranidou I, Nena E, Karaglani M, Nicolaidou C, Asimaki A, Konstantinidis T, Constantinidis TC, Kolios G, Kakolyris S, Agorastos T, Chatzaki E., Tumour Biol 39(4), 2017
PMID: 28381193
Sexual Behavior in Germany.
Haversath J, Gärttner KM, Kliem S, Vasterling I, Strauss B, Kröger C., Dtsch Arztebl Int 114(33-34), 2017
PMID: 28855044
Cost-effectiveness of human papillomavirus vaccination in Germany.
Damm O, Horn J, Mikolajczyk RT, Kretzschmar MEE, Kaufmann AM, Deleré Y, Ultsch B, Wichmann O, Krämer A, Greiner W., Cost Eff Resour Alloc 15(), 2017
PMID: 28878573
Cervical cancer control in Latin America: A call to action.
Bychkovsky BL, Ferreyra ME, Strasser-Weippl K, Herold CI, de Lima Lopes G, Dizon DS, Schmeler KM, Del Carmen M, Randall TC, Nogueira-Rodrigues A, de Carvalho Calabrich AF, St Louis J, Vail CM, Goss PE., Cancer 122(4), 2016
PMID: 26670695
Factors influencing uptake of HPV vaccination among girls in Germany.
Schülein S, Taylor KJ, König J, Claus M, Blettner M, Klug SJ., BMC Public Health 16(), 2016
PMID: 27645711
[HPV-induced anal lesions].
Wieland U, Kreuter A., Hautarzt 66(6), 2015
PMID: 25859930
Human papillomaviruses in urological malignancies: a critical assessment.
Tolstov Y, Hadaschik B, Pahernik S, Hohenfellner M, Duensing S., Urol Oncol 32(1), 2014
PMID: 24140249
HPV vaccine uptake after introduction of the vaccine in Germany: an analysis of administrative data.
Hense S, Hillebrand K, Horn J, Mikolajczyk R, Schulze-Rath R, Garbe E., Hum Vaccin Immunother 10(6), 2014
PMID: 24637921
Cost-effectiveness and equity impacts of three HPV vaccination programmes for school-aged girls in New Zealand.
Blakely T, Kvizhinadze G, Karvonen T, Pearson AL, Smith M, Wilson N., Vaccine 32(22), 2014
PMID: 24662710

13 References

Daten bereitgestellt von Europe PubMed Central.

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide.
Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N., J. Pathol. 189(1), 1999
PMID: 10451482
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM., Int. J. Cancer 127(12), 2010
PMID: 21351269
Against which human papillomavirus types shall we vaccinate and screen? The international perspective.
Munoz N, Bosch FX, Castellsague X, Diaz M, de Sanjose S, Hammouda D, Shah KV, Meijer CJ., Int. J. Cancer 111(2), 2004
PMID: 15197783
Genital human papillomavirus infection.
Dunne EF, Markowitz LE., Clin. Infect. Dis. 43(5), 2006
PMID: 16886157

AUTHOR UNKNOWN, 0

AUTHOR UNKNOWN, 0
Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women.
Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, Hedrick J, Jaisamrarn U, Limson G, Garland S, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Jenkins D, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G; HPV PATRICIA Study Group, Denham I, Garland S, Mindel A, O'Sullivan M, Skinner SR, Waddell R, de Carvalho N, Naud P, Teixeira JC, De Sutter P, Poppe WA, Tjalma W, Aoki FY, Diaz-Mitoma F, Dionne M, Ferguson L, Miller M, Papp K, Ramjattan B, Romanowski B, Somani R, Apter D, Astikainen S, Karppa T, Kekki M, Keranen H, Kudjoi N, Kuortti M, Kupari M, Kyha-Osterlund L, Isaksson R, Lehtinen M, Levanen H, Liljamo T, Loonberg K, Niemi L, Paavonen J, Palmroth J, Petaja T, Rekonen S, Romppanen U, Siitari-Mattila M, Tuomivaara L, Vilkki M, Belling KH, Gent T, Grubert T, Harlfinger W, Holst A, Hopker WD, Jensen-El Tobgui S, Merder G, Peters K, Schoenian S, Schulze K, Schwarz T, Wackernagel C, Boselli F, Mojana G, Salmeron J, Benitez G, Crisostomo C, Del Rosario-Raymundo R, Germar MJ, Limson G, Raymundo J, Remollino MC, Villanueva G, Villanueva S, Zamora JD, Zamora L, Bajo J, Bayas J, Campins M, Castellsague X, Castro M, Centeno C, Cruzet F, Rodriguez L, Torne A, Vidart JA, Chow SN, Yu MH, Yuan CC, Huang SC, Ho HN, Chen RJ, Lin HH, Chu TY, Angsuwathana S, Jaisamrarn U, Wilawan K, Abdulhakim E, Cruickshank M, Kitchener H, Lewis D, Pavel I, Robinson J, Szarewski A, Ackerman R, Ault K, Bennett N, Caldwell M, Chambers C, Chatterjee A, Civitarese L, Demars L, De Santis T, Downs L, Ferris D, Fine P, Gall S, Harper D, Hedrick J, Herzig W, Hiraoka M, Huh W, Kamemoto L, Klein T, Koltun W, Kong A, Lalezari J, Lee P, Leeman L, Luber S, Martens M, Michelson J, Nebel W, Peterson C, Pitts K, Rosen J, Rosenfeld W, Scutella M, Seidman L, Sperling M, Sperling R, Stager M, Stapleton J, Swenson K, Thoming C, Twiggs L, Waldbaum A, Wheeler CM, Yardley M, Zbella E, Kiviat N, Klugman KP, Nieminen P, Bergeron C, Eisenstein E, Karron R, Marks R, Nolan T, Tay SK, Albers S, Bollaerts P, Camier A, Colau B, De Breyne A, Genevrois S, Issaka Z, Martens N, Peeters P, Smoes N, Spiessens B, Tavares F, Tonglet A, Vanden-Dunghen S, Vilain AS, Ward KR, Alt E, Iskaros B, Limaye A, Liu-Jarin X, Luff RD, McNeeley M, Provenzano C, Winkler B, Molijn A, Quint W, Struijk L, Van de Sandt M, Van Doorn LJ, Greenacre M, Baronikova S, Zahaf T, David MP, Declerck L, Dupin J, Maroye JL., Lancet 374(9686), 2009
PMID: 19586656
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years.
Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Tay EH, Garcia P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Joura EA, Kurman RJ, Majewski S, Munoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan J, Lupinacci LC, Giacoletti KE, Sings HL, James M, Hesley TM, Barr E., J. Infect. Dis. 199(7), 2009
PMID: 19236279
HPV vaccine: Cervarix.
Szarewski A., Expert Opin Biol Ther 10(3), 2010
PMID: 20132062
Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis.
Malagon T, Drolet M, Boily MC, Franco EL, Jit M, Brisson J, Brisson M., Lancet Infect Dis 12(10), 2012
PMID: 22920953
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.
Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GW, Ferris DG, Steben M, Bryan J, Taddeo FJ, Railkar R, Esser MT, Sings HL, Nelson M, Boslego J, Sattler C, Barr E, Koutsky LA; Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators., N. Engl. J. Med. 356(19), 2007
PMID: 17494926

Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®

Quellen

PMID: 23518405
PubMed | Europe PMC

Suchen in

Google Scholar